[go: up one dir, main page]

MX2016010085A - Metodos para tratar lesion del cerebro leve. - Google Patents

Metodos para tratar lesion del cerebro leve.

Info

Publication number
MX2016010085A
MX2016010085A MX2016010085A MX2016010085A MX2016010085A MX 2016010085 A MX2016010085 A MX 2016010085A MX 2016010085 A MX2016010085 A MX 2016010085A MX 2016010085 A MX2016010085 A MX 2016010085A MX 2016010085 A MX2016010085 A MX 2016010085A
Authority
MX
Mexico
Prior art keywords
brain injury
methods
mild brain
treat mild
subject
Prior art date
Application number
MX2016010085A
Other languages
English (en)
Other versions
MX383323B (es
Inventor
Bansal Vishal
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2016010085A publication Critical patent/MX2016010085A/es
Publication of MX383323B publication Critical patent/MX383323B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción proporciona métodos para tratar lesión del cerebro leve y otros trastornos neurológicos en un sujeto, que comprenden administrar al sujeto una cantidad efectiva de un compuesto que comprende grelina.
MX2016010085A 2014-02-05 2015-02-05 Grelina para uso en el tratamiento de lesión del cerebro traumática leve. MX383323B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461936143P 2014-02-05 2014-02-05
US14/486,636 US9119832B2 (en) 2014-02-05 2014-09-15 Methods of treating mild brain injury
PCT/US2015/014692 WO2015120203A1 (en) 2014-02-05 2015-02-05 Methods of treating mild brain injury

Publications (2)

Publication Number Publication Date
MX2016010085A true MX2016010085A (es) 2016-11-15
MX383323B MX383323B (es) 2025-03-13

Family

ID=53753927

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010085A MX383323B (es) 2014-02-05 2015-02-05 Grelina para uso en el tratamiento de lesión del cerebro traumática leve.

Country Status (14)

Country Link
US (5) US9119832B2 (es)
EP (1) EP3102226B1 (es)
JP (1) JP6675315B2 (es)
KR (1) KR102354384B1 (es)
AU (1) AU2015214028B2 (es)
BR (1) BR112016017886A8 (es)
CA (1) CA2945487C (es)
DK (1) DK3102226T3 (es)
EA (1) EA039367B1 (es)
ES (1) ES2714911T3 (es)
IL (2) IL246957B (es)
MX (1) MX383323B (es)
NZ (1) NZ722600A (es)
WO (1) WO2015120203A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
EP3182992A4 (en) * 2014-08-19 2018-05-16 Oxeia Biopharmaceuticals Inc. Methods of treating mild brain injury
US20170266257A1 (en) * 2014-09-25 2017-09-21 Oxeia Biopharmaceuticals, Inc. Methods of treating traumatic brain injury
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
WO2020033502A1 (en) * 2018-08-08 2020-02-13 Neuro Biofuels Limited Methods for treatment of brain injury and brain dysfunction
CA3165738A1 (en) * 2019-12-23 2021-07-01 Oxeia Biopharmaceuticals, Inc. Treatment of mild traumatic brain injury
CN111666409B (zh) * 2020-05-28 2022-02-08 武汉大学 一种基于综合深度胶囊网络的复杂评论文本的整体情感智能分类方法
JP2025531796A (ja) * 2022-09-07 2025-09-25 オクセイア・バイオファーマシューティカルズ・インコーポレイテッド 軽度外傷性脳損傷の治療
WO2025096549A1 (en) * 2023-10-30 2025-05-08 Ohio State Innovation Foundation Compounds and methods for the treatment of brain injuries

Family Cites Families (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
DE2122529A1 (de) 1971-05-06 1972-12-14 Max Planck Gesellschaft zur Förde rung der Wissenschaften e V , 3400 Gottin gen Thiophosphatanaloge der Nucleosid di und tnphosphate sowie Verfahren zu ihrer Herstellung
US4228155A (en) 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223021A (en) 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223020A (en) 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228157A (en) 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228156A (en) 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228158A (en) 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223019A (en) 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4226857A (en) 1979-03-30 1980-10-07 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4224316A (en) 1979-03-30 1980-09-23 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4410512A (en) 1981-12-28 1983-10-18 Beckman Instruments, Inc. Combinations having synergistic pituitary growth hormone releasing activity
US4410513A (en) 1981-12-28 1983-10-18 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
JPS58501861A (ja) 1981-12-28 1983-11-04 ベツクマン・インストルメンツ・インコ−ポレ−テツド 下垂体成長ホルモン放出活性を有する合成ペプチド
US5416073A (en) 1983-08-10 1995-05-16 The Adminstrators Of The Tulane Educational Fund Growth hormone-releasing peptides and method of treating animals, therewith
US4485101A (en) 1983-10-11 1984-11-27 Administrators Of The Tulane Educational Fund Peptides
US4650787A (en) 1985-04-25 1987-03-17 Schally Andrew Victor Biologically active octapeptides
DE3642648A1 (de) 1986-12-13 1988-06-23 Boehringer Ingelheim Kg Verwendung von 6-allyl-2-amino-5,6,7,8-tetrahydro-4h-thiazolo-(5,4-d)azepin zur freisetzung von wachstumshormon
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US4880777A (en) 1987-09-01 1989-11-14 Eastman Kodak Company Synthetic peptides having growth hormone releasing activity
ATE122357T1 (de) 1988-01-28 1995-05-15 Polygen Holding Corp Polypeptide mit hormonwachstumsbefreiender wirkung.
DE68919213T2 (de) 1988-01-28 1995-05-11 Polygen Holding Corp Polypeptidverbindungen mit wachstumshormonfreisetzender aktivität.
WO1989010933A1 (en) 1988-05-11 1989-11-16 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US5668254A (en) 1990-05-11 1997-09-16 Romano Deghenghi D-2-alkyl-tryptophan and peptides containing same
US5872100A (en) 1990-05-11 1999-02-16 Deghenghi; Romano Peptides containing D-2-Alkyl-Tryptophan
IL98910A0 (en) 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5486505A (en) 1990-07-24 1996-01-23 Polygen Holding Corporation Polypeptide compounds having growth hormone releasing activity
US5206235A (en) 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
ATE196548T1 (de) 1991-05-10 2000-10-15 Genentech Inc Auswählen von agonisten und antagonisten von liganden
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5576301A (en) 1991-11-27 1996-11-19 The Penn State Research Foundation Low molecular growth potentiating peptides
US5283241A (en) 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
EP0663834A4 (en) 1992-09-25 1996-01-24 Smithkline Beecham Corp GROWTH HORMONE RELEASING PEPTIDES.
US5583130A (en) 1992-09-25 1996-12-10 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5317017A (en) 1992-09-30 1994-05-31 Merck & Co., Inc. N-biphenyl-3-amido substituted benzolactams stimulate growth hormone release
US5374721A (en) 1992-10-14 1994-12-20 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
EP0669830A4 (en) 1992-11-06 1997-02-26 Merck & Co Inc SUBSTITUTED DIPEPTIDE ANALOGS, WHICH SUPPORT THE RELEASE OF GROWTH HORMONE.
US5726319A (en) 1992-11-06 1998-03-10 Merck & Co., Inc. Biphenyl substituted dipeptide analogs promote release of growth hormone
AU5727194A (en) 1992-11-13 1994-06-08 The Administrators Of The Tulane Eductional Fund Ghrh agonists
RO115804B1 (ro) 1992-12-11 2000-06-30 Merck & Co Inc Derivati de spiropiperidine, procedee de preparare si compozitii farmaceutice ale acestora
US5536716A (en) 1992-12-11 1996-07-16 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
US5284841A (en) 1993-02-04 1994-02-08 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5430144A (en) 1993-07-26 1995-07-04 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5434261A (en) 1993-07-26 1995-07-18 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5691377A (en) 1993-07-30 1997-11-25 University Of Maryland Eastern Shore And University Of Maryland College Park Use of N-methyl-aspartic acid for enhancing growth and altering body composition
US5545735A (en) 1993-10-04 1996-08-13 Merck & Co., Inc. Benzo-Fused Lactams promote release of growth hormone
US5438136A (en) 1993-11-02 1995-08-01 Merck & Co., Inc. Benzo-fused macrocycles promote release of growth hormone
US5494919A (en) 1993-11-09 1996-02-27 Merck & Co., Inc. 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5492916A (en) 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5492920A (en) 1993-12-10 1996-02-20 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
JPH10506091A (ja) 1993-11-09 1998-06-16 メルク エンド カンパニー インコーポレーテッド 成長ホルモン放出促進性のピペリジン、ピロリジンおよびヘキサヒドロ−１ｈ−アゼピン類
CA2176140A1 (en) 1993-11-24 1995-06-01 Meng Hsin Chen Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
US5721251A (en) 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
AU1371895A (en) 1993-12-13 1995-07-03 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5606054A (en) 1993-12-14 1997-02-25 Merck & Co., Inc. Heterocyclic-fused lactams promote release of growth hormone
US5550212A (en) 1993-12-17 1996-08-27 The Administrators Of The Tulane Educational Fund Analogues of hGH-RH(1-29)NH2 having antagonistic activity
US5721250A (en) 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
DE69427650T2 (de) 1993-12-23 2001-11-22 Novo Nordisk A/S, Bagsvaerd Verbindungen mit wachstumshormon-freisetzenden eigenschaften
NZ277486A (en) 1993-12-23 1997-03-24 Novo Nordisk As Synthetic peptides with growth hormone releasing properties
US5579301A (en) 1994-02-28 1996-11-26 Micom Communications Corp. System for, and method of, managing voice congestion in a network environment
AU2695795A (en) 1994-06-13 1996-01-05 Merck & Co., Inc. Piperazine compounds promote release of growth hormone
US5783582A (en) 1994-07-20 1998-07-21 Merck & Co., Inc. Piperidines and hexahydro-1H-azepines spiro substituted at the 4-position promote release of growth hormone
IL114955A (en) 1994-08-17 1999-12-22 Novo Nordisk As N-substituted naphthofused lactams and pharmaceutical compositions containing them
EP0783521B8 (en) 1994-09-27 2003-04-09 Ardana Bioscience Limited Polypeptide compounds containing d-2-alkyltryptophan capable of promoting the release of growth hormone
US5767118A (en) 1994-10-26 1998-06-16 Merck & Co., Inc. 4-Heterocyclic peperidines promote release of growth hormone
US5798337A (en) 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
AU705744B2 (en) 1995-01-27 1999-06-03 Sapphire Therapeutics, Inc. Compounds with growth hormone releasing properties
WO1996024587A1 (en) 1995-02-09 1996-08-15 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU4534596A (en) 1995-02-09 1996-08-27 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5656606A (en) 1995-02-17 1997-08-12 Merck & Co., Inc. Camphor compounds promote release of growth hormone
US5731317A (en) 1995-03-10 1998-03-24 Merck & Co., Inc. Bridged piperidines promote release of growth hormone
JPH11503454A (ja) 1995-04-14 1999-03-26 ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド 成長ホルモン放出因子の類似体
US5559128A (en) 1995-04-18 1996-09-24 Merck & Co., Inc. 3-substituted piperidines promote release of growth hormone
WO1996033189A1 (en) 1995-04-19 1996-10-24 Merck & Co., Inc. Process for the preparation of spiroindolines
WO1996035713A1 (en) 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
MX9709278A (es) 1995-05-29 1998-03-31 Pfizer Dipeptidos que promueven la liberacion de la hormona de crecimiento, composiciones que los contienen y uso de los mismos.
HUP9802821A3 (en) 1995-06-22 2000-03-28 Novo Nordisk As Compounds with growth hormone releasing properties
AU6772996A (en) 1995-08-21 1997-03-12 Eli Lilly And Company 2-acylaminopropanamides as growth hormone secretagogues
AU7169696A (en) 1995-09-26 1997-04-17 Merck & Co., Inc. 3-spirolactam, 3-spiroamino, 3-spirolactone and 3-spirobenzopyran piperidines and pyrrolidines promote release of growth hormone
JPH11513989A (ja) 1995-10-27 1999-11-30 メルク エンド カンパニー インコーポレーテッド 成長ホルモン分泌促進薬の湿式造粒製剤
HUP9902208A3 (en) 1995-10-27 2001-05-28 Merck & Co Inc Polymorphic forms of a growth hormone secretagogue and medicaments containing them
US5767124A (en) 1995-10-27 1998-06-16 Merck & Co., Inc. Polymorphic forms of a growth hormone secretagogue
CZ128298A3 (cs) 1995-10-27 1998-07-15 Merck And Co., Inc. Způsob výroby N-/1(R)-/(1,2-dihydro-1-methansulfonylspiro/3H-indol-3,4´-piperdin/-1´-yl)karbonyl/-2-(fenylmethyloxy)-ethyl/-2-amino-2-methylpropanamidu
SE9504019D0 (sv) 1995-11-13 1995-11-13 Pharmacia Ab Method for production of proteins
EP0876402B1 (en) 1995-12-13 2004-10-13 Merck & Co., Inc. Growth hormone secretagogue receptor family
AU4974596A (en) 1995-12-15 1997-07-14 Salk Institute For Biological Studies, The Betide-substituted gnrh antagonists
GB2308362A (en) 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
WO1997022367A1 (en) 1995-12-20 1997-06-26 Merck & Co., Inc. Radiolabeled growth hormone secretagogue
IT1277113B1 (it) 1995-12-20 1997-11-04 Romano Deghenghi Composti oligopeptidici contenenti d-2-alchiltriptofano in grado di promuovere la liberazione dell'ormone della crescita
EP0869974B1 (en) 1995-12-22 2009-03-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
ES2197258T3 (es) 1996-01-11 2004-01-01 PHARMACIA & UPJOHN COMPANY Formulacion acuosa de liberacion prolongada que comprende el factor de liberacion de la hormona de crecimiento bovino.
FR2744123B1 (fr) 1996-01-26 1998-04-17 Carelli Claude Marcel Henri Molecules biologiquement actives plus particulierement peptidiques ayant un effet potentialisateur de l'activite biologique de l'hormone de croissance
WO1997034604A1 (en) 1996-03-21 1997-09-25 Merck & Co., Inc. 4-spiroindoline piperidines promote release of growth hormone
US5837861A (en) 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
US5804578A (en) 1996-04-03 1998-09-08 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
JP2000510453A (ja) 1996-04-19 2000-08-15 ノボ ノルディスク アクティーゼルスカブ 成長ホルモン遊離特性を有する化合物
KR20000010626A (ko) 1996-04-24 2000-02-25 한센 핀 베네드, 안네 제헤르 성장호르몬 방출성을 갖는 화합물
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US5942489A (en) 1996-05-03 1999-08-24 The Administrators Of The Tulane Educational Fund HGH-RH(1-29)NH2 analogues having antagonistic activity
US5807985A (en) 1996-06-11 1998-09-15 Deghenghi; Romano Oligopeptide compounds containing D-2-alkyltryptophan capable of promoting the release of growth hormone
JP4425992B2 (ja) 1996-07-22 2010-03-03 サファイア セラピューティクス，インコーポレイティド 成長ホルモン放出特性を有する化合物
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US5877182A (en) 1996-09-13 1999-03-02 Merck & Co., Inc. Piperidines promote release of growth hormone
AU4342097A (en) 1996-09-13 1998-04-02 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
JP2001502319A (ja) 1996-10-15 2001-02-20 藤沢薬品工業株式会社 成長ホルモンの放出を促進するベンズオキセピン誘導体
WO1998025622A1 (en) 1996-12-09 1998-06-18 Merck & Co., Inc. Methods and compositions for preventing and treating bone loss
WO1998025897A1 (en) 1996-12-12 1998-06-18 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
WO1998046569A1 (fr) 1997-04-11 1998-10-22 Sumitomo Pharmaceuticals Co., Ltd. Derives de benzene
WO1998046220A1 (en) 1997-04-14 1998-10-22 Merck & Co., Inc. Combination therapy for the prevention and treatment of osteoporosis
US6329368B1 (en) 1997-05-09 2001-12-11 The Regents Of The University Of California Endocrine modulation with positive modulators of AMPA type glutamate receptors
JP2000514838A (ja) 1997-05-14 2000-11-07 藤沢薬品工業株式会社 成長ホルモンの放出を促進するピペリジノ誘導体
WO1998058950A1 (en) 1997-06-20 1998-12-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
ES2283055T3 (es) 1997-06-25 2007-10-16 Pfizer Inc. Derivados dipeptidos como secretagogos de la hormona de crecimiento.
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
ZA987385B (en) 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
EP1021190B1 (en) 1997-08-22 2006-11-08 Kaken Pharmaceutical Co., Ltd. Amid derivatives as growth hormone release promotors
WO1999009998A1 (en) 1997-08-29 1999-03-04 The University Of North Carolina At Chapel Hill Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases
JP2002525265A (ja) 1998-08-14 2002-08-13 アドミニストレイターズ オブ ザ トゥレーン エジュケーショナル ファウンド 成長ホルモン放出活性を有する化合物
KR100699404B1 (ko) 1999-02-18 2007-03-23 가켄 세야쿠 가부시키가이샤 성장 호르몬 분비촉진제로서의 신규 아미드 유도체
ATE304373T1 (de) 1999-12-28 2005-09-15 Kaken Pharma Co Ltd Nervenschutzmittel
US6967237B2 (en) 2000-05-30 2005-11-22 Merck & Co., Inc. Ghrelin analogs
KR20030033002A (ko) 2000-07-24 2003-04-26 아다나 바이오싸이언스 리미티드 그렐린 길항제
IL145106A0 (en) 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US20030027755A1 (en) 2000-12-08 2003-02-06 Jian Guan Compositions and methods for the rescue of white matter
CU23157A1 (es) 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
EP1312363A1 (en) 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
US7937145B2 (en) 2002-03-22 2011-05-03 Advanced Neuromodulation Systems, Inc. Dynamic nerve stimulation employing frequency modulation
CN100411683C (zh) 2002-05-21 2008-08-20 阿斯比奥制药株式会社 含有生长素释放肽的药物组合物
US20040081652A1 (en) 2002-07-15 2004-04-29 The Johns Hopkins University Neuronal and optic nerve gene expression patterns
JP2006515271A (ja) 2002-07-23 2006-05-25 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス グレリン類似体
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
US7491695B2 (en) 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2004111077A1 (en) 2003-06-18 2004-12-23 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor
EP1651362A4 (en) 2003-07-03 2011-07-20 Chief R Davis APPARATUS AND METHOD FOR INSPECTING SEWAGE PIPING USING SMALL MOBILE VEHICLES
DK1648922T3 (da) 2003-07-31 2011-03-14 Tranzyme Pharma Inc Rumligt definerede makrocykliske forbindelser, der er anvendelige til opdagelse af lægemidler
CA2533820C (en) 2003-07-31 2016-12-13 Tranzyme Pharma Spatially-defined macrocycles incorporating peptide bond surrogates
WO2005039625A1 (en) * 2003-10-28 2005-05-06 Rheoscience A/S Growth hormone secretagogue receptor agonists
EP1529533A1 (en) 2003-11-06 2005-05-11 Sahltech I Göteborg AB Use of GH secretagogues in hypoxic-ischemic brain injury
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US8420602B2 (en) 2004-09-14 2013-04-16 Landon C. G. Miller Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders
WO2006045314A2 (en) 2004-10-27 2006-05-04 Gastrotech Pharma A/S Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease
WO2006079077A2 (en) 2005-01-20 2006-07-27 Acadia Pharmaceuticals Inc. Use of diltiazem or analogs thereof as modulators of ghrelin receptor
AR052741A1 (es) * 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
US7829589B2 (en) 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
US7923442B2 (en) 2005-10-06 2011-04-12 Uti Limited Partnership Glutathione peroxidase mimetics and uses thereof
GB0603295D0 (en) 2006-02-18 2006-03-29 Ardana Bioscience Ltd Methods and kits
CU23592A1 (es) 2006-02-28 2010-11-11 Ct Ingenieria Genetica Biotech Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6
NZ571183A (en) 2006-03-13 2010-09-30 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation
US7763707B2 (en) 2006-03-13 2010-07-27 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation
CA2652815C (en) 2006-05-25 2015-12-15 Biogen Idec Ma Inc. Methods of treating stroke
BRPI0711965A2 (pt) 2006-06-07 2012-01-24 Genzyme Corp terapia de gene para esclerose lateral amiotrófica e outras enfermidades da medula espinal
WO2007146287A2 (en) 2006-06-09 2007-12-21 Leptos Biomedical, Inc. Dynamic nerve stimulation employing frequency modulation
US8088733B2 (en) 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
CA2660517A1 (en) 2006-08-11 2008-02-14 University Of Miyazaki Spinal nerve repair promoting therapeutics containing ghrelin or its derivatives or substances that act on ghs-rla as an active ingredient
WO2008100629A2 (en) 2007-02-16 2008-08-21 Synvista Therapeutics, Inc. Glutathione peroxidase mimetics for the treatment of dermatoses
WO2008113072A2 (en) 2007-03-15 2008-09-18 Board Of Regents, The University Of Texas System Gpcr enhanced neuroprotection to treat brain injury
US20100216706A1 (en) 2007-05-15 2010-08-26 Horvath Tamas L Ghrelin Protects Substantia Nigra Dopamine Neurons
TW200916113A (en) 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
US8324151B2 (en) 2007-11-20 2012-12-04 The Feinstein Institute For Medical Research Treatment of sepsis and septic shock using ghrelin and growth hormone
EP2067481A1 (en) 2007-12-03 2009-06-10 Charité-Universitätsmedizin Berlin Therapeutic use of desacyl ghrelin
KR100977625B1 (ko) 2008-01-08 2010-08-23 경희대학교 산학협력단 그렐린을 함유하는 척수 손상 치료용 약학적 조성물
JP5766614B2 (ja) 2009-01-09 2015-08-19 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムＴｈｅ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｅｘａｓ Ｓｙｓｔｅｍ 神経新生促進化合物
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
DK2396036T3 (en) 2009-02-13 2017-10-16 Immunomedics Inc Immune conjugates with an intracellular cleavable compound
US8883721B2 (en) 2009-05-12 2014-11-11 Mcgill University Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
EP2683364B1 (en) 2011-03-10 2017-01-18 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
WO2012149111A1 (en) 2011-04-26 2012-11-01 The Regents Of The University Of California Methods of promoting cns neuronal repair by inhibiting lrp-1
US20120302526A1 (en) 2011-05-27 2012-11-29 Regents Of The University Of Colorado, A Body Corporate Methods for treating post-traumatic stress disorder
DK2723426T3 (da) 2011-06-21 2019-11-04 Brent Buchine Automatisk blandeindretning og afgivelsessystem
CU23963B1 (es) 2011-07-01 2013-12-11 Ct De Ingeniería Genética Y Biotecnología Composiciones farmacéuticas a partir de derivados de la c-ficocianina y combinaciones con interferones del tipo i para el tratamiento de enfermedades cerebrales isquémicas y neurodegenerativas
SG10201504605RA (en) 2011-09-23 2015-07-30 Technophage Investigação E Desenvolvimento Em Biotecnologia Sa Anti-Tumor Necrosis Factor-Alpha Agents And Uses Thereof
EA201490746A3 (ru) 2011-10-07 2016-09-30 Флорида Стейт Юниверсити Рисеч Фондэйшн Применение прогестерона при профилактике и после острого периода для улучшения исходов, связанных с сотрясением мозга
WO2013113916A2 (en) 2012-02-03 2013-08-08 Zealand Pharma A/S Ghrelin analogues
WO2013119650A1 (en) 2012-02-06 2013-08-15 Board Of Regents Of The University Of Nebraska Delivery of biotherapeutics to the brain
PE20142451A1 (es) 2012-02-27 2015-02-04 Amunix Operating Inc Composiciones de conjugados de xten y metodos para realizar las mismas
NZ629722A (en) 2012-02-29 2017-03-31 Pulmatrix Operating Co Inc Inhalable dry powders
US20140018299A1 (en) 2012-07-10 2014-01-16 Banyan Biomarkers, Inc. Method and device to detect, monitor and promote neural regeneration and improvement of cognitive function in a subject suffering from neural injury
US20140024053A1 (en) 2012-07-20 2014-01-23 Banyan Biomarkers, Inc. Methods, kits and devices for detecting bii-spectrin, and breakdown products thereof, as biomarkers for the diagnosis of neural injury
US20140255517A1 (en) 2013-03-06 2014-09-11 Emory University Managing post-traumatic stress disorder
US20160058726A1 (en) 2013-04-16 2016-03-03 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of brain injury
AU2014296629A1 (en) 2013-07-16 2016-02-18 Liat Mintz Ghrelin splice variant for treating neuronal damage, neurodegenerative disease, Parkinsons disease, Alzheimers disease, and/or depression
US9119832B2 (en) * 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
EP3182992A4 (en) 2014-08-19 2018-05-16 Oxeia Biopharmaceuticals Inc. Methods of treating mild brain injury
US20170266257A1 (en) 2014-09-25 2017-09-21 Oxeia Biopharmaceuticals, Inc. Methods of treating traumatic brain injury
WO2016134215A1 (en) 2015-02-19 2016-08-25 The Regents Of The University Of California Methods of treating mild brain injury and post-traumatic stress disorder

Also Published As

Publication number Publication date
AU2015214028A1 (en) 2016-08-18
AU2015214028B2 (en) 2020-08-27
BR112016017886A8 (pt) 2018-04-17
US9119832B2 (en) 2015-09-01
IL246957B (en) 2022-07-01
JP6675315B2 (ja) 2020-04-01
WO2015120203A1 (en) 2015-08-13
US20160367637A1 (en) 2016-12-22
JP2017506625A (ja) 2017-03-09
US20210052702A1 (en) 2021-02-25
CA2945487A1 (en) 2015-08-13
IL246957A0 (en) 2016-09-29
EA201691567A1 (ru) 2017-04-28
IL293712B2 (en) 2023-08-01
MX383323B (es) 2025-03-13
CA2945487C (en) 2022-12-06
US10105416B2 (en) 2018-10-23
US10617740B2 (en) 2020-04-14
IL293712A (en) 2022-08-01
EA039367B1 (ru) 2022-01-19
KR20160110520A (ko) 2016-09-21
US20190216900A1 (en) 2019-07-18
IL293712B1 (en) 2023-04-01
US20220401520A1 (en) 2022-12-22
EP3102226A1 (en) 2016-12-14
KR102354384B1 (ko) 2022-01-21
US20150216939A1 (en) 2015-08-06
DK3102226T3 (en) 2019-03-25
NZ722600A (en) 2023-06-30
BR112016017886A2 (pt) 2017-10-10
EP3102226B1 (en) 2018-12-19
ES2714911T3 (es) 2019-05-30
US11241483B2 (en) 2022-02-08

Similar Documents

Publication Publication Date Title
MX2016010085A (es) Metodos para tratar lesion del cerebro leve.
CL2017002242A1 (es) Método para tratar un tumor cerebral
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
MX2018004947A (es) Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados.
BR112017006940A2 (pt) triazolopirazinonas como inibidores de pde1
CL2017001046A1 (es) Inhibidoes del bromodominio
MX370506B (es) Método para tratar trastorno de estrés post-traumático.
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
DOP2017000254A (es) Imidazopirazinonas como inhibidores de pde1
BR112019001398A2 (pt) métodos para tratamento de câncer de próstata
MX2014011855A (es) Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides.
PE20151526A1 (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod
BR112017024304A2 (pt) processo para a preparação de um extrato de cérebro animal
MX2017014782A (es) Metodo para el tratamiento de enfermedad neurologica.
MX2018012230A (es) Métodos para tratar enfermedades oculares.
MX2017005064A (es) Metodos para tratar afecciones oculares.
ECSP16082599A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
IL250658A0 (en) Methods for treating mild brain injury
ECSP16071574A (es) Hexahidrofuropirroles como inhibidores de pde1
MX2020005952A (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.
MX2015011371A (es) Anticuerpos monoclonales anti-+)--metanfetamina.